Cell Damage in Light Chain Amyloidosis: FIBRIL INTERNALIZATION, TOXICITY AND CELL-MEDIATED SEEDING
- PMID: 27462073
- PMCID: PMC5025671
- DOI: 10.1074/jbc.M116.736736
Cell Damage in Light Chain Amyloidosis: FIBRIL INTERNALIZATION, TOXICITY AND CELL-MEDIATED SEEDING
Abstract
Light chain (AL) amyloidosis is an incurable human disease characterized by the misfolding, aggregation, and systemic deposition of amyloid composed of immunoglobulin light chains (LC). This work describes our studies on potential mechanisms of AL cytotoxicity. We have studied the internalization of AL soluble proteins and amyloid fibrils into human AC16 cardiomyocytes by using real time live cell image analysis. Our results show how external amyloid aggregates rapidly surround the cells and act as a recruitment point for soluble protein, triggering the amyloid fibril elongation. Soluble protein and external aggregates are internalized into AC16 cells via macropinocytosis. AL amyloid fibrils are shown to be highly cytotoxic at low concentrations. Additionally, caspase assays revealed soluble protein induces apoptosis, demonstrating different cytotoxic mechanisms between soluble protein and amyloid aggregates. This study emphasizes the complex immunoglobulin light chain-cell interactions that result in fibril internalization, protein recruitment, and cytotoxicity that may occur in AL amyloidosis.
Keywords: amyloid; apoptosis; cardiomyocytes; cell internalization; endocytosis; fibril fragmentation; in vivo imaging; light chain amyloidosis; protein aggregation; toxicity.
© 2016 by The American Society for Biochemistry and Molecular Biology, Inc.
Figures









Similar articles
-
Protease-sensitive regions in amyloid light chains: what a common pattern of fragmentation across organs suggests about aggregation.FEBS J. 2022 Jan;289(2):494-506. doi: 10.1111/febs.16182. Epub 2021 Sep 15. FEBS J. 2022. PMID: 34482629 Free PMC article.
-
Mesenchymal stromal cells protect human cardiomyocytes from amyloid fibril damage.Cytotherapy. 2017 Dec;19(12):1426-1437. doi: 10.1016/j.jcyt.2017.08.021. Epub 2017 Oct 14. Cytotherapy. 2017. PMID: 29037943 Free PMC article.
-
Differential effects on light chain amyloid formation depend on mutations and type of glycosaminoglycans.J Biol Chem. 2015 Feb 20;290(8):4953-4965. doi: 10.1074/jbc.M114.615401. Epub 2014 Dec 23. J Biol Chem. 2015. PMID: 25538238 Free PMC article.
-
Immunoglobulin light chain amyloid aggregation.Chem Commun (Camb). 2018 Sep 20;54(76):10664-10674. doi: 10.1039/c8cc04396e. Chem Commun (Camb). 2018. PMID: 30087961 Free PMC article. Review.
-
Antibodies gone bad - the molecular mechanism of light chain amyloidosis.FEBS J. 2023 Mar;290(6):1398-1419. doi: 10.1111/febs.16390. Epub 2022 Feb 17. FEBS J. 2023. PMID: 35122394 Review.
Cited by
-
Cardiac amyloidosis-An underdiagnosed cause of heart failure: A case report and review of literature.Clin Case Rep. 2022 Dec 2;10(12):e6525. doi: 10.1002/ccr3.6525. eCollection 2022 Dec. Clin Case Rep. 2022. PMID: 36478969 Free PMC article.
-
Arrhythmias and Device Therapies in Cardiac Amyloidosis.J Clin Med. 2024 Feb 25;13(5):1300. doi: 10.3390/jcm13051300. J Clin Med. 2024. PMID: 38592132 Free PMC article. Review.
-
Concurrent structural and biophysical traits link with immunoglobulin light chains amyloid propensity.Sci Rep. 2017 Dec 1;7(1):16809. doi: 10.1038/s41598-017-16953-7. Sci Rep. 2017. PMID: 29196671 Free PMC article.
-
Cardiac Troponin in Patients With Light Chain and Transthyretin Cardiac Amyloidosis: JACC: CardioOncology State-of-the-Art Review.JACC CardioOncol. 2024 Feb 20;6(1):1-15. doi: 10.1016/j.jaccao.2023.12.006. eCollection 2024 Feb. JACC CardioOncol. 2024. PMID: 38510286 Free PMC article. Review.
-
Assays for Light Chain Amyloidosis Formation and Cytotoxicity.Methods Mol Biol. 2019;1873:123-153. doi: 10.1007/978-1-4939-8820-4_8. Methods Mol Biol. 2019. PMID: 30341607 Free PMC article.
References
-
- Falk R. H. (2005) Diagnosis and management of the cardiac amyloidoses. Circulation 112, 2047–2060 - PubMed
-
- Kumar S. K., Gertz M. A., Lacy M. Q., Dingli D., Hayman S. R., Buadi F. K., Short-Detweiler K., Zeldenrust S. R., Leung N., Greipp P. R., Lust J. A., Russell S. J., Kyle R. A., Rajkumar S. V., and Dispenzieri A. (2011) Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score. Mayo Clin. Proc. 86, 12–18 - PMC - PubMed
-
- Glenner G. G., Cuatrecasas P., Isersky C., Bladen H. A., and Eanes E. D. (1969) Physical and chemical properties of amyloid fibers: II. Isolation of a unique protein constituting the major component from human splenic amyloid fibril concentrates. J. Histochem. Cytochem. 17, 769–780 - PubMed
-
- Olsen K. E., Sletten K., and Westermark P. (1998) Fragments of the constant region of immunoglobulin light chains are constituents of AL-amyloid proteins. Biochem. Biophys. Res. Commun. 251, 642–647 - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical